NASDAQ:ADIL

Adial Pharmaceuticals Stock Forecast, Price & News

$2.70

0.00 (0.00 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.66

▼

$2.76

50-Day Range

$2.02

▼

$2.83

52-Week Range

$1.14

▼

$4.00

Volume40,244 shs

Average Volume224,402 shs

Market Capitalization$48.90 million

P/E RatioN/A

Dividend YieldN/A

Beta0.61

30 days | 90 days | 365 days | Advanced Chart

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction
June 7, 2021 | markets.businessinsider.com

Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction
June 7, 2021 | finance.yahoo.com

Adial Pharmaceuticals (NASDAQ:ADIL) Trading 7.2% Higher
June 4, 2021 | americanbankingnews.com

Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
June 3, 2021 | finance.yahoo.com

Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
May 18, 2021 | feeds.benzinga.com

Adial Pharma Seeks To Treat The Pandemic Of Addiction
April 7, 2021 | finance.yahoo.com

Adial Pharmaceuticals to Participate at the Benzinga Biotech Small Cap Conference on March 24th
March 23, 2021 | finance.yahoo.com

Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel
March 17, 2021 | finance.yahoo.com

Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
March 15, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADIL
Previous Symbol
CUSIPN/A
CIK1513525
Webwww.adialpharma.com
Phone434-422-9800
Employees8
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.28 per share
Price / Book9.64

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares18,110,000
Market Cap$48.90 million
Next Earnings Date6/17/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.40 out of 5 stars

Medical Sector

1815th out of 2,099 stocks

Pharmaceutical Preparations Industry

754th out of 831 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Adial Pharmaceuticals.

2.0 Community Rank

Outperform Votes
Adial Pharmaceuticals has received 95 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Adial Pharmaceuticals has received 140 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Adial Pharmaceuticals has received 59.57% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Adial Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adial Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adial Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $375,000.00 in company stock.
Percentage Held by Insiders
Only 33.90% of the stock of Adial Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 4.37% of the stock of Adial Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Adial Pharmaceuticals is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adial Pharmaceuticals is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adial Pharmaceuticals has a P/B Ratio of 9.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What stocks does MarketBeat like better than Adial Pharmaceuticals?

Wall Street analysts have given Adial Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adial Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Adial Pharmaceuticals.

How has Adial Pharmaceuticals' stock been impacted by Coronavirus?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADIL stock has increased by 100.0% and is now trading at $2.70.
View which stocks have been most impacted by COVID-19.

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:

Mr. William B. Stilley III, M.B.A., MBA, Chairman, Pres & CEO (Age 53, Pay $614.1k)
Dr. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 61, Pay $375k)
Mr. Joseph M. Truluck M.B.A., MBA, CFO, COO, Treasurer & Sec. (Age 43, Pay $225.03k)
Dr. Jack W. Reich, Head of Regulatory (Age 72, Pay $17.01k)
Mr. Alex Lugovoy, Chief Bus. Officer
Mr. Mark H. Peikin, Chief Strategy Officer
Mr. Lawrence Goldman, Controller (Age 65)

Who are some of Adial Pharmaceuticals' key competitors?

Some companies that are related to Adial Pharmaceuticals include Biofrontera (BFRA), Strongbridge Biopharma (SBBP), 180 Life Sciences (ATNF), OptiNose (OPTN), Synlogic (SYBX), Anebulo Pharmaceuticals (ANEB), Abeona Therapeutics (ABEO), 4D pharma (LBPS), ObsEva (OBSV), AcelRx Pharmaceuticals (ACRX), Assembly Biosciences (ASMB), Clearside Biomedical (CLSD), Lantern Pharma (LTRN), Genprex (GNPX) and Matinas BioPharma (MTNB).
View all of ADIL's competitors.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu Biopharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (0.21%), Dimensional Fund Advisors LP (0.18%), Commonwealth Equity Services LLC (0.13%), Barclays PLC (0.09%), Rede Wealth LLC (0.09%) and Oppenheimer & Co. Inc. (0.08%). Company insiders that own Adial Pharmaceuticals stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends for Adial Pharmaceuticals.

Which institutional investors are buying Adial Pharmaceuticals stock?

ADIL stock was bought by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, Barclays PLC, Rede Wealth LLC, Oppenheimer & Co. Inc., Dimensional Fund Advisors LP, and Commonwealth Equity Services LLC. Company insiders that have bought Adial Pharmaceuticals stock in the last two years include James W Jr Newman, and William B Stilley III.
View insider buying and selling activity for Adial Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.70.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals has a market capitalization of $48.90 million.

How many employees does Adial Pharmaceuticals have?

Adial Pharmaceuticals employs 8 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is www.adialpharma.com.

Where are Adial Pharmaceuticals' headquarters?

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here